First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NCT06799065 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Breast Cancer Recurrent
Ovarian Cancer
High-grade Serous Ovarian Carcinoma
Triple Negative Breast Cancer

Interventions

DRUG: ATX-295

Sponsor

Accent Therapeutics